Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma
Status:
Unknown status
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the investigators' study is to prospectively evaluate whether low-dose
thalidomide adjuvant therapy will improve the outcome of radiofrequency ablation for
hepatocellular carcinoma (HCC).